The companies also announced an agreement to expand their existing collaboration to include promotion of oral Abilify in 14 European countries starting April 1, 2013. Under the agreement, Otsuka and Lundbeck will jointly promote Abilify in Denmark, Finland, Germany, Italy, Spain, Sweden and the UK. Lundbeck will promote Abilify in Austria, Belgium, Ireland, Netherlands, Poland, Portugal and Romania.

The agreement provides Lundbeck with the rights to promote all formulations of Abilify that are currently being marketed, sold and distributed by Otsuka in the European Union including the swallowable tablet, oral solution, orally-disintegrating tablet and the IM rapid injectable.